Kyra S Jefferson-George1, David A Wolk1, Edward B Lee2, Corey T McMillan3. 1. Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. 2. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: mcmillac@upenn.edu.
Abstract
INTRODUCTION: Primary age-related tauopathy (PART) is a neuropathological diagnosis characterized by tau neurofibrillary tangles (NFTs) in the absence of amyloid plaque pathology. Although most individuals over 50 years of age have evidence of NFTs, the clinical and cognitive consequences of PART are not known. METHODS: We evaluated 226 neuropathologically confirmed PART cases from the National Alzheimer's Coordinating Center database who participated in a total of 846 longitudinal neuropsychological assessments from the Alzheimer's Disease Center program's Uniform Data Set. Mixed-effects statistical models tested whether cognitive decline was associated with Braak stage NFT burden. RESULTS: Higher stages of NFT burden in PART, with no evidence or minimal evidence of amyloid pathology, were associated with more rapid decline on tasks involving episodic and semantic memory along with tests of processing speed and attention. DISCUSSION: We conclude that PART has cognitive consequences that should be considered in the context of emerging tau-targeted therapies in age-associated neurodegenerative diseases.
INTRODUCTION: Primary age-related tauopathy (PART) is a neuropathological diagnosis characterized by tau neurofibrillary tangles (NFTs) in the absence of amyloid plaque pathology. Although most individuals over 50 years of age have evidence of NFTs, the clinical and cognitive consequences of PART are not known. METHODS: We evaluated 226 neuropathologically confirmed PART cases from the National Alzheimer's Coordinating Center database who participated in a total of 846 longitudinal neuropsychological assessments from the Alzheimer's Disease Center program's Uniform Data Set. Mixed-effects statistical models tested whether cognitive decline was associated with Braak stage NFT burden. RESULTS: Higher stages of NFT burden in PART, with no evidence or minimal evidence of amyloid pathology, were associated with more rapid decline on tasks involving episodic and semantic memory along with tests of processing speed and attention. DISCUSSION: We conclude that PART has cognitive consequences that should be considered in the context of emerging tau-targeted therapies in age-associated neurodegenerative diseases.
Authors: D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen Journal: J Neuropathol Exp Neurol Date: 2003-11 Impact factor: 3.685
Authors: Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2009 Apr-Jun Impact factor: 2.703
Authors: Haobo Zhang; Perminder S Sachdev; Wei Wen; Nicole A Kochan; John D Crawford; Henry Brodaty; Melissa J Slavin; Simone Reppermund; Kristan Kang; Julian N Trollor Journal: PLoS One Date: 2013-11-05 Impact factor: 3.240
Authors: Lilah M Besser; Charles Mock; Merilee A Teylan; Jason Hassenstab; Walter A Kukull; John F Crary Journal: J Neuropathol Exp Neurol Date: 2019-03-01 Impact factor: 3.685
Authors: W Robert Bell; Yang An; Yusuke Kageyama; Collin English; Gay L Rudow; Olga Pletnikova; Madhav Thambisetty; Richard O'Brien; Abhay R Moghekar; Marilyn S Albert; Peter V Rabins; Susan M Resnick; Juan C Troncoso Journal: Alzheimers Dement Date: 2018-12-11 Impact factor: 21.566
Authors: Lilah M Besser; Walter A Kukull; Merilee A Teylan; Eileen H Bigio; Nigel J Cairns; Julia K Kofler; Thomas J Montine; Julie A Schneider; Peter T Nelson Journal: J Neuropathol Exp Neurol Date: 2018-08-01 Impact factor: 3.685
Authors: Long Xie; Sandhitsu R Das; Laura E M Wisse; Ranjit Ittyerah; Paul A Yushkevich; David A Wolk Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson Journal: Alzheimers Dement Date: 2019-05-02 Impact factor: 21.566
Authors: Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust Journal: J Neurosci Date: 2020-11-20 Impact factor: 6.167
Authors: Sandhitsu R Das; Long Xie; Laura E M Wisse; Nicolas Vergnet; Ranjit Ittyerah; Salena Cui; Paul A Yushkevich; David A Wolk Journal: Alzheimers Dement Date: 2019-09-06 Impact factor: 21.566
Authors: Merilee Teylan; Charles Mock; Kathryn Gauthreaux; Yen-Chi Chen; Kwun C G Chan; Jason Hassenstab; Lilah M Besser; Walter A Kukull; John F Crary Journal: Brain Date: 2020-02-01 Impact factor: 13.501